Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle
AM Starzer, M Preusser… - Therapeutic advances in …, 2022 - journals.sagepub.com
The introduction of immune checkpoint inhibitors has changed the therapeutic possibilities
for various cancer types. However, despite the success in some entities, a significant fraction …
for various cancer types. However, despite the success in some entities, a significant fraction …
[HTML][HTML] Prognosis of patients with hepatocellular carcinoma treated with immunotherapy–development and validation of the CRAFITY score
B Scheiner, K Pomej, MM Kirstein, F Hucke… - Journal of …, 2022 - Elsevier
Background & Aims Immunotherapy with atezolizumab plus bevacizumab represents the
new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC) …
new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC) …
Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design
Canakinumab is a human IgGκ monoclonal antibody, with high affinity and specificity for IL-
1β. The Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) trial …
1β. The Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) trial …
[HTML][HTML] Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
AS Laino, D Woods, M Vassallo, X Qian… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Inflammatory mediators, including acute phase reactants and cytokines, have
been reported to be associated with clinical efficacy in patients with melanoma and other …
been reported to be associated with clinical efficacy in patients with melanoma and other …
Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients
Background KRAS gene is the most common type of mutation reported in colorectal cancer
(CRC). KRAS mutation-mediated regulation of immunophenotype and immune pathways in …
(CRC). KRAS mutation-mediated regulation of immunophenotype and immune pathways in …
[HTML][HTML] C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
T Yoshida, J Ichikawa, I Giuroiu, AS Laino… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background High C reactive protein (CRP) levels have been reported to be associated with
a poor clinical outcome in a number of malignancies and with programmed cell death …
a poor clinical outcome in a number of malignancies and with programmed cell death …
[HTML][HTML] Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable …
Immune checkpoint inhibitors (ICIs) with atezolizumab plus bevacizumab are promising
agents for unresectable hepatocellular carcinoma (HCC). We tried to guide the treatment …
agents for unresectable hepatocellular carcinoma (HCC). We tried to guide the treatment …
A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies
D Cao, H Xu, X Xu, T Guo, W Ge - Oncoimmunology, 2018 - Taylor & Francis
Objective: Nivolumab has been used for treating non-small cell lung cancer (NSCLC)
worldwide. Whether neutrophil-lymphocyte ratio (NLR) can predict the prognosis of NSCLC …
worldwide. Whether neutrophil-lymphocyte ratio (NLR) can predict the prognosis of NSCLC …
Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC
Y Tian, X Zhai, W Yan, H Zhu, J Yu - Cancer medicine, 2021 - Wiley Online Library
Immune checkpoint blockades (ICBs) have changed the standard of care of squamous and
adenocarcinoma non‐small cell lung cancer (NSCLC). Whereas detailed researches …
adenocarcinoma non‐small cell lung cancer (NSCLC). Whereas detailed researches …
[HTML][HTML] Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic …
AR Naqash, JD McCallen, E Mi… - … for immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Systemic immune activation, hallmarked by C-reactive protein (CRP) and
interleukin-6 (IL-6), can modulate antitumor immune responses. In this study, we evaluated …
interleukin-6 (IL-6), can modulate antitumor immune responses. In this study, we evaluated …